StockData
CG Oncology, Inc. logo

CG Oncology, Inc. (CGON) stock

CGONNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30
$84.78+10.38 (+13.95%)

Close on Nov 16, 2026Market cap $7.51BP/E –Yield –

CG Oncology enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

CG Oncology's enterprise value was $5.39B on Nov 11, 2026, against $2.83B a year earlier. Over the last 3 years it ranged from $22.21M to $5.61B, with a median of $1.91B.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$5.39B+109.4%
2025Dec 31, 2025$2.57B+84.3%
2024Dec 31, 2024$1.40B–

More CG Oncology figures

See a number that looks wrong?